0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessABSTRACT Background COVID-19 exhibits a steep age gradient of infection fatality rate. There has been debate about whether extra protection of elderly and other vulnerable individuals (precision shielding) is feasible, and, if so, to what extent. Methods We used systematically retrieved data from national seroprevalence studies conducted in the pre-vaccination era. Studies were identified through SeroTracker and PubMed searches (last update May 17, 2022). Studies were eligible if they targeted representative general populations without high risk of bias. Seroprevalence estimates were noted for children, non-elderly adults, and elderly adults, using cut-offs of 20, and 60 years (or as close to these ages, if they were not available). Results Thirty-eight national seroprevalence studies from 36 different countries were included in the analysis. 26/38 also included pediatric populations. 25/38 studies were from high-income countries. The median ratio of seroprevalence in the elderly versus non-elderly adults (or non-elderly in general, if pediatric and adult population data were not offered separately) was 0.90-0.95 in different analyses with large variability across studies. In 5 studies (all of them in high-income countries), there was significant protection of the elderly with ratio <0.40. The median was 0.83 in high-income countries and 1.02 in other countries. The median ratio of seroprevalence in children versus adults was 0.89 and only one study showed a significant ratio of <0.40. Conclusion Precision shielding of elderly community-dwelling populations before the availability of vaccines was feasible in some high-income countries, but most countries failed to achieve any substantial focused protection of this age group. summary 38 COVID-19 nationally representative seroprevalence studies conducted before vaccination campaigns were systematically identified. Median seroprevalence ratio in elderly versus non-elderly adults was 0.90-0.95, indicating no generally achieved precision shielding of elderly. In 5 studies, substantial protection (ratio <0.40) was observed.
Cathrine Axfors, Angelo Maria Pezzullo, Despina G. Contopoulos‐Ioannidis, Alexandre Apostolatos, John P A Ioannidis (2022). Differential COVID-19 infection rates in children, adults, and elderly: evidence from 38 pre-vaccination national seroprevalence studies. , DOI: https://doi.org/10.1101/2022.06.28.22277034.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Preprint
Year
2022
Authors
5
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1101/2022.06.28.22277034
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access